Table 3.
Comparison of lipid subgroup analyses in fibrate trials
| Study (drug) | CVD reduction (P) entire cohort |
Lipid subgroup criteria | CVD reduction (P) subgroup |
|---|---|---|---|
| Helsinki Heart Study (Gemfibrozil) [8,28,29] | −34% (0.02) | TG ≥204 mg/dl HDL-C <42 mg/dla | −78% (0.002) |
| BIP (Bezafibrate) [10] | −7.3% (0.24) | TG >200 mg/dl | −39.5% (0.02) |
| FIELD (Fenofibrate) [11,30•] | −11% (0.16) | TG ≥204 mg/dl HDL-C = <40 mg/dlb | −27% (0.005) |
| ACCORD (Fenofibrate) [15••] | 8% (0.26) | TG ≥204 mg/dl HDL-C = <34 mg/dl | −31% |
Data are percentage reduction in the occurrence of the primary cardiovascular endpoint of each study respectively in the entire cohort and in a subgroup defined by the presence of low HDL-C and/or hypertriglyceridemia upon entry into the study. TG, triglycerides.
a
HHS subgroup further defined by the presence of BMI >26 kg/m2.
b
In FIELD, low HDL-C defined as <40 mg/dl in men and <50 mg/dl for women.